202217-19-4

Basic information

• Product Name: 6-Chloro-5-Methyl-3-nitro-2-pyridinaMine
• Synonyms: 6-Chloro-5-Methyl-3-nitro-2-pyridinaMine;6-Chloro-5-Methyl-3-nitropyridin-2-aMine
• CAS NO: 202217-19-4
• Molecular Formula: C₆H₆ClN₃O₂
• Molecular Weight: 187.58374
• Mol File: 202217-19-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 6-Chloro-5-Methyl-3-nitro-2-pyridinaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-5-Methyl-3-nitro-2-pyridinaMine(202217-19-4)
• EPA Substance Registry System: 6-Chloro-5-Methyl-3-nitro-2-pyridinaMine(202217-19-4)

Safety Data

• Hazardous Substances Data: 202217-19-4(Hazardous Substances Data)

Usage

General Description

6-Chloro-5-Methyl-3-nitro-2-pyridinaMine is a chemical compound with the molecular formula C6H6ClN3O2. It is a derivative of pyridine and contains a nitro group, a methyl group, and a chlorine atom attached to the pyridine ring. 6-Chloro-5-Methyl-3-nitro-2-pyridinaMine may have applications in the pharmaceutical industry, particularly in the synthesis of biologically active molecules. Its specific properties and potential uses would depend on further research and development.

Upstream product

• 58596-88-6 2,6-dichloro-3-methyl-5-nitropyridine 
• 1241373-24-9 2-chloro-5-methyl-3-nitropyridine 1-oxide 
• 23056-40-8 2-chloro-5-methyl-3-nitro-pyridine 
• 58584-94-4 2,6-dichloro-3-methylpyridine 
• 91668-83-6 2-Chloro-3-methylpyridine N-oxide 
• 20173-49-3 2-chloro-5-methylpyridine-N-oxide 
• 18368-76-8 2 chloro-3-methylpyridine 
• 18368-64-4 2-chloro-5-methylpyridine 

Relevant articles and documents

Sulfide Analogues of Flupirtine and Retigabine with Nanomolar KV7.2/KV7.3 Channel Opening Activity

The potassium channel openers flupirtine and retigabine have proven to be valuable analgesics or antiepileptics. Their recent withdrawal due to occasional hepatotoxicity and tissue discoloration, respectively, leaves a therapeutic niche unfilled. Metabolic oxidation of both drugs gives rise to the formation of electrophilic quinones. These elusive, highly reactive metabolites may induce liver injury in the case of flupirtine and blue tissue discoloration after prolonged intake of retigabine. We examined which structural features can be altered to avoid the detrimental oxidation of the aromatic ring and shift oxidation toward the formation of more benign metabolites. Structure–activity relationship studies were performed to evaluate the KV7.2/3 channel opening activity of 45 derivatives. Sulfide analogues were identified that are devoid of the risk of quinone formation, but possess potent KV7.2/3 opening activity. For example, flupirtine analogue 3-(3,5-difluorophenyl)-N-(6-(isobutylthio)-2-(pyrrolidin-1-yl)pyridin-3-yl)propanamide (48) has 100-fold enhanced activity (EC50=1.4 nm), a vastly improved toxicity/activity ratio, and the same efficacy as retigabine in vitro.

IMIDAZOPYRIDINE COMPOUND

A compound represented by the following general formula (1), or a salt or hydrate thereof: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom, provided that a compound wherein R1 is a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and R2 is a hydrogen atom is excluded.